WHAT’S NEW?
- In this study, we present the outcome of NHL patients treated with
AHSCT in Malaysia (the very first report from Malaysia), where data in
resource limited countries within South East Asian region are lacking
- Our study illustrates the outcomes of HDT and AHSCT in NHL patients in
a resource limited country with a comparable transplant related
mortality.
- Due to the higher incidence of aggressive lymphomas, this article also
highlighted upfront AHSCT as a possible cost-effective strategy to
reduce the risk of relapse.